Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

- Read more about Teva Completes Acquisition of Anda, Inc
Teva Pharmaceutical Industries Ltd. announced that it has completed its acquisition of Anda, Inc., a leading distributor of generic pharmaceuticals in the U.S., from Allergan plc
- Read more about Jubilant DraxImage Receives FDA Approval for RUBY-FILL Rubidium 82 Generator and Elution System
Jubilant Pharma Ltd, announced that the U.S. Food and Drug Administration has approved RUBY-FILL®, an innovative technology for Positron Emission Tomography (PET) myocardial perfusion imaging (MPI). Comprised of a Rubidium-82 (Rb-82) Generator and precedent setting Elution System, RUBY-FILL® is used to produce a personalized patient dose of Rubidium Rb 82 chloride used to evaluate regional myocardial perfusion in adult patients with suspected or existing coronary artery disease (CAD) which is an important component of diagnosing CAD.
- Read more about DelSiTech, Bayer partner to develop innovative drug delivery technology for ophthalmology
DelSiTech Ltd, a Finnish drug delivery technology and drug development company, and Bayer have signed a collaboration and technology licence agreement for the worldwide application of DelSiTech’s Silica Matrix drug delivery platform to a number of Bayer’s compounds in ophthalmology.
- Read more about Amgen & Arrowhead Pharma begin Two Cardiovascular Collaborations
Amgen and Arrowhead Pharmaceuticals Inc. announced two license and collaboration agreements to develop and commercialize RNA interference (RNAi) therapies for cardiovascular disease. These are the first programs to utilize Arrowhead's proprietary subcutaneous RNAi delivery platform. RNAi molecules may be designed to target and shut down specific gene products that contribute to various diseases.
- Read more about Zydus and Medicines for Malaria Venture collaborate to Develop Potential New Antimalarial Drug
Zydus Cadila, a research-driven, global healthcare provider and Medicines for Malaria Venture (MMV) announced a collaboration to develop the investigational antimalarial compound, MMV674253. Zydus will lead the development of the novel compound and MMV will provide support including scientific expertise and access to tools in the field of malaria drug development and delivery.
- Read more about Life saving drug, D-Penicillamine is not availble in indian market
Life saving drug (D-Penicillamine) is not available across India. And CDSCO working faster on availability of drug in the market.
- Read more about Cancer Research UK, MSD and Verastem Collaborate to Trial New Combination of Immunotherapy Drugs
MSD, Verastem, Inc. and Cancer Research UK will trial a new combination of immunotherapy drugs in mesothelioma, non small cell lung and pancreatic cancers. The trial will run through the ECMC network at centres in Edinburgh-Dundee, Southampton, Glasgow, Leicester and Belfast.

(adsbygoogle = window.adsbygoogle || []).push({});
- Read more about Nanobiomed Inc® Discovered a New Nuclear Staining Molecule and Eco-Friendly Natural Source for Cancer Diagnostics: Prextrolin®
Nanobiomed Inc®., a nanomedicine and biotechnology company announced its leading-edge development of a new molecule for use in tissue and cancer diagnostics.
- Read more about Sun Pharma announce clinical trial results of psoriasis drug
Sun Pharmaceutical Industries Ltd announce latebreaking data from two pivotal Phase-3 clinical trials (reSURFACE 1 and 2) achieving the primary endpoint with tildrakizumab, an investigational IL-23p19 inhibitor, in patients with moderate-to-severe plaque psoriasis at the 25th European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria. As indicated in a previous press release, top line results from these studies were announced on May 4, 2016.
- Read more about Administering additional antibiotic prior to C-section reduces infection rates by 50%
“Infection during pregnancy and during the postpregnancy period is a major health problem for both mom and baby, and a common underlying cause of death,” said Alan T. N. Tita, M.D., Ph.D.; professor in the UAB Division of Maternal-Fetal Medicine and the Center for Women’s Reproductive Health, and principal investigator of the study. “Women who have a C-section are at significantly increased risk for infection compared to those who deliver vaginally. A major national goal is to reduce the risk of infection after surgery, and this finding is the culmination of investigative work over decades.”